FDA could use a "scalpel" to carefully address commercial confidentiality and share more information with patient groups, an ultra rare disease advocate told the agency. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
